Evidence map›Paper›PMID 40489436›Full record

ArticlePloS one2025

Aldo-keto reductase family 1 member C3 (AKR1C3) gene polymorphism (rs12529) is associated with breast cancer in Bangladeshi population: A case-control study and computational investigation.

Md Akeruzzaman Shaon, Farzana Ansari, Zimam Mahmud, Sonia Tamanna, Md Nazid Bin Ibrahim, Nazia Fairooz Alam, Md Naiem Hossain, Md Zakir Hossain Howlader

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Md Akeruzzaman ShaonLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.ORCID 0009-0007-3472-2916
Farzana AnsariLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Zimam MahmudLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.ORCID 0000-0002-2971-5283
Sonia TamannaLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Md Nazid Bin IbrahimLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Nazia Fairooz AlamLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Md Naiem HossainLaboratory of Nutritional, Gene and Human Disease, Department of Biochemistry and Molecular Biology, University of DhakaDhaka, Bangladesh.
Md Zakir Hossain HowladerLaboratory of Nutrition and Health Research, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.ORCID 0000-0002-3175-8709

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is defined as the unchecked growth of breast cells, with imbalances in prostaglandin and steroid hormone metabolism contributing to disease risk by altering prostaglandin types and forms (strong and weak) of steroid hormones. The AKR1C3 enzyme plays a key role in managing these metabolic processes. This study investigated the association between the AKR1C3 gene polymorphism (rs12529) and the risk of developing breast cancer in Bangladeshi individuals. A case-control investigation was conducted with a total of 620 samples, involving 310 individuals diagnosed with breast cancer and 310 healthy subjects. Herein, DNA extraction was performed via an organic process, whereas genotyping was employed via the PCR‒RFLP technique. Statistical assessments were conducted to analyze the association of polymorphisms, while molecular dynamics simulation and diverse computational techniques were employed to anticipate the functional and structural impacts of the SNP. Our study discovered that the rs12529 polymorphism of the AKR1C3 gene has an enhanced risk of susceptibility to breast malignancy (p = 0.016, OR = 1.97, 95% CI = 1.22 to 3.16 for the GG genotype in additive model 2). The recessive model (GG vs CC+CG) also showed an enhanced risk of susceptibility to breast malignancy (p = 0.0004, OR = 1.95, 95% CI =  1.40 to 2.73). In both premenopausal women and postmenopausal women, the GG genotype (for the recessive model) significantly increased breast cancer risk by 1.92-fold and 1.95-fold, respectively. However, no significant associations were observed regarding tumor grade or size in breast cancer development. In-silico analyses indicated that the H5Q (rs12529) mutation may decrease protein stability but is typically tolerated or functionally neutral. Molecular dynamics simulations revealed that H5Q leads to increased structural fluctuations and surface exposure, potentially causing the mutant AKR1C3 enzyme to operate differently from the wild type. In conclusion, rs12529 significantly increases the incidence of breast cancer in the population of Bangladesh. Computational analyses further revealed that the H5Q (rs12529) mutation in AKR1C3 leads to decreased stability and altered functional changes with notable conformational changes.

Indexed as

Aldo-Keto Reductase Family 1 Member C3Breast NeoplasmsGenetic Predisposition to DiseaseHydroxyprostaglandin DehydrogenasesPolymorphism, Single NucleotideAdultBangladeshCase-Control StudiesFemaleGenotypeHumansMiddle AgedMolecular Dynamics SimulationAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3Hydroxyprostaglandin Dehydrogenases

Identifiers

PMID40489436
PMCPMC12148162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.